After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...